Latest Paratek Pharmaceuticals Inc. Stories
POINT RICHMOND, Calif., Oct. 14, 2014 /PRNewswire/ -- Transcept Pharmaceuticals, Inc.
Merger to result in NASDAQ-listed biopharmaceutical company whose lead asset is a novel Phase 3-ready, oral and intravenous antibiotic drug candidate designed to address the treatment needs of patients
BOSTON, Sept. 10 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, PTK 0796, a first-in-class aminomethylcycline, will be the subject of several poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Dr.
BOSTON, Oct. 8 /PRNewswire-FirstCall/ -- Paratek Pharmaceuticals, Inc.
BOSTON, Oct. 26 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced positive Phase 2 data for the Company's lead antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC).